Images List Premium Download Classic

Sleep Disorders

Sleep Disorders-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Substituted pyrazino[2,2-a]isoquinoline derivatives
Hoffmann-la Roche Inc.
February 08, 2018 - N°20180037582

The present invention relates to compounds of formula of formula i wherein r, r1, r2 and l are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula i.
Process for the preparation of histamine h3 receptor modulators
Janssen Pharmaceutica Nv
January 25, 2018 - N°20180022704

The present invention is directed to novel processes for the preparation of histamine h3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.
Composition and method for improving sleep duration and quality
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
January 25, 2018 - N°20180021411

An intervention for sleep disorders comprises: collagen, a gelatin peptide, or the amino acid glycine; l-theanine; lactucopicrin, deoxylactucopicrin, or another lactucopicrin derivative; hyaluronic acid; epigallocatechin gallate; and quinic acid. The intervention helps regulate pro-inflammatory biomarkers that are often associated with insomnia development and progression. These biomarkers include cytokines and enzymes associated with tryptophan degradation. Inhibition of these enzymes and cytokines ...
Sleep Disorders Patent Pack
Download + patent application PDFs
Sleep Disorders Patent Applications
Download + Sleep Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Sleep Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Mouth closing device
January 11, 2018 - N°20180008452

The present invention relates to a device to urge the mouth closed during sleep to reduce snoring and/or treat sleep disorders such as sleep apnea. In one aspect, the device includes a jaw-blocking object that is secured beneath the chin of a user and also contacting the clavicular region of the upper chest area. In another aspect, a device ...
Methods and systems for diagnosing sleep disorders
Oasis Diagnostics Corporation
January 04, 2018 - N°20180003723

Methods and compositions for risk detection, early diagnosis, prognosis, and monitoring of sleepiness in an individual by measuring the amount of specific biomarkers present in a bodily fluid and comparing them to a reference level of biomarkers in a sample from a healthy person, a person previously diagnosed with sleepiness, or an earlier sample from the individual of interest.
3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
November 30, 2017 - N°20170342103

Where r1, r2, r3, r3′, r4, r6a, r6a, r11a, and r11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (tbi), stress, and epilepsy.
Sleep Disorders Patent Pack
Download + patent application PDFs
Sleep Disorders Patent Applications
Download + Sleep Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Sleep Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of ...
Arena Pharmaceuticals, Inc.
November 09, 2017 - N°20170320831

Pyrazole derivatives of formula (ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5ht2a receptor. Formula (ia). Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot ...
Tetrahydronaphthyridine derivatives as mglur2-negative allosteric modulators, compositions, and their use
Merck Canada Inc.
October 26, 2017 - N°20170305902

The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (i) or a pharmaceutically acceptable salt thereof, wherein r1, r2, l, x1, x2, and x3, are as defined herein. The compounds of the invention, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising them, are useful as non-competitive mglur2 antagonists, or mglur2 negative allosteric modulators (nams), and may ...
Combination of valerian root extract and lavender oil for use in the treatment of sleep ...
October 19, 2017 - N°20170296612

The present invention relates to a combination of valerian root extract and lavender oil for treating of sleep disorders, as well as to a combination of preparation comprising valerian root extract and lavender oil.
Removable mandibular myo-stimulator
Achaemenid, Llc
October 12, 2017 - N°20170290699

An oral appliance for the treatment of sleep disorders, such as obstructive sleep apnea, in a user is presented. The oral appliance may include a mouthpiece configured to receive a user's dentition. The mouthpiece may include an oxygen sensor, a pressure sensor, an airflow sensor, an actigraphy sensor, a noise detector, and at least one stimulator for providing stimulation to ...
Apparatus and methods for the treatment of sleep apnea
Lumen Devices, Llc
September 21, 2017 - N°20170266034

A medical apparatus for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient is provided. The apparatus comprises an elongate member with a middle portion, a first fixation element and a second fixation element. The middle portion applies a force to a segment of a patient's airway.
2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of ...
Shire International Gmbh
September 14, 2017 - N°20170260185

The present invention provides compounds of formula (i) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4. 5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (dat) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, tourette syndrome, angelman syndrome, attention deficit disorder (add), attention deficit hyperactivity disorder (adhd), obesity, pain, obsessive-compulsive disorder, movement ...
Compositions and methods for treating insomnia
Eisai R&d Management Co., Ltd.
September 07, 2017 - N°20170252342

In the present invention, compound such as (1r,2s)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-n-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
Sleep Disorders Patent Pack
Download + patent application PDFs
Sleep Disorders Patent Applications
Download + Sleep Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Sleep Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
19-nor c3, 3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
August 31, 2017 - N°20170246191

And pharmaceutically acceptable salts thereof; wherein , r1, r2, r3a, r3b, r4a, r4b, r5, r6, and r7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement ...
Spiro-thiazolones
August 31, 2017 - N°20170246153

Wherein x1, x2, x3, x4, r2, r3, r4, r5, r6 and r7 are as defined herein, which act as v1a receptor modulators, and in particular as v1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments for treatment of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive ...
Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof
Universite De Montpellier
August 24, 2017 - N°20170239237

This invention concerns pyrroloquinoline derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive ...
Prevention or treatment of sleep disorders using dexmedetomidine formulation
Bioxcel Corporation
August 24, 2017 - N°20170239221

There is provided a composition suitable for oral transmucosal administration (sublingual) comprising dexmedetomidine. The composition is useful for the treatment of sleep disorders such as insomnia and capable of providing sleep on demand. The composition comprises an effective amount of dexmedetomidine or pharmaceutically acceptable salts thereof, solvates thereof, or derivatives thereof, formulated for delivery of dexmedetomidine across a subject's oral ...
19-nor neuroactive steroids and methods of use thereof
August 17, 2017 - N°20170233432

And pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.
System and method for delivering a therapy and sensing a biological activity in the mouth
Scientific Partners, Llc
August 17, 2017 - N°20170231807

Methods, devices, and systems are disclosed for controlled delivery of a therapy, such as a stimulant, to a mouth of a subject via an oral device positioned in a secured configuration in the mouth. At least one of a tongue position stimulator (tst) and tongue position sensor (tse) is provided, according to certain aspects. According to another aspect, a stimulus ...
Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery ...
August 10, 2017 - N°20170224911

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, attention deficit disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood ...
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Jazz Pharmaceuticals, Inc.
August 10, 2017 - N°20170224825

Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into gbl. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of ghb. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of ...
Loading